Treatment progress of relapsed/refractory Hodgkin lymphoma

VernacularTitle:复发难治霍奇金淋巴瘤治疗进展
Author: Yunchen WEI ¹ ; Wei XU
Author Information

1. 210029,南京医科大学第一附属医院江苏省人民医院血液科
Keywords: Hodgkin disease; Recurrence; Refractory
From: Journal of Leukemia & Lymphoma 2018;27(12):705-707,711
CountryChina
Language:Chinese
Abstract: Hodgkin lymphoma (HL) is a curable malignancy for most patients, while the treatment of relapsed and refractory (R/R) HL is still facing severe challenges. In the 60th American Society of Hematology (ASH) Annual Meeting, many researches reported the latest development of the treatment of R/R HL. For chemosensitive patients, autologous stem cell transplantation after high-dose of salvage chemotherapy still remains the standard treatment method. The emerging of antibody drug conjugate, inhibitors of programmed death-1, chimeric antigen receptor T-cell immunotherapy and the combinations of multiple drugs have brought an increasing options for R/R HL treatment. This paper reviews the progress of R/R HL therapy.